Home A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z


12.21.2017 | Victoria Lawman

It can also cause elevations in hepatic enzymes such as gamma-glutamyl transferase and alkaline phosphatase. In 1981, it was shown that phenobarbital, one of primidone's metabolites, only induced a significant porphyrin at high concentrations in vitro. It was first reported to exacerbate hepatic porphyria in 1975.

In a subsequent pilot trial in which children who experienced improvement were switched to placebo, the results were much more disappointing, with the two subjects who experienced subjective improvement also experiencing this on placebo. Two trials of primidone for athetosis have been published. In one, small doses of primidone successfully treated eighteen out of thirty-one children.

In juvenile myoclonic epilepsy (JME), it is a second-line therapy, reserved for when the valproates and/or lamotrigine do not work and when other second-line therapies—acetazolamid work either. In the United States, primidone is approved for adjunctive (in combination with other drugs) and monotherapy (by itself) use in generalized tonic-clonic seizures, simple partial seizures, and complex partimple partial seizures, and myoclonic seizures. Licensed for generalized tonic-clonic and complex partial seizures in the United Kingdom.

In May 2005, Dr. Out of all of the risk factors, usage of primidone and inadequate seizure control were the greatest; with ORs of 4.089 and 3.084, respectively. Schaffer et al. M. It can also cause hyperactivity in children; this most commonly occurs at low serum levels. Polytherapy was also associated with poor seizure control. They had been looking for factors associated with depression in epilepsy patients. There is one case of an individual developing catatonic schizophrenia when her serum concentration of primidone went above normal. 1999 reported that one of their treatment failures, a 45-year-old woman taking 50 mg a day along with lithium 600 mg/day, clozapine 12.5 mg/day, trazodone 50 mg/day, and alprazolam 4 mg/day for three and a half months experienced auditory hallucinations that led to discontinuation of primidone. Lopez-Gomez's team reported an association between the use of primidone and depression in epilepsy patients; this same study reported that inadequate seizure control, posttraumatic epilepsy, and polytherapy were also risk factors.

This syndrome consists of fever, rash, peripheral leukocytosis, lymphadenopathy, and occasionally hepatic necrosis. Primidone is one of the anticonvulsants associated with anticonvulsant hypersensitivity syndrome, others being carbamazepine, phenytoin, and phenobarbital.

Hayes's 33%). Schaffer, Charles B. All subjects with a permanent and complete treatment response were either Bipolar I or Bipolar NOS. In 1999, Drs. Caretto conducted a follow-up study on those earlier reports, as no one else had done so in the six years following their publication, and found it to be roughly as (permanently) effective for refractory bipolar disorder as Hayes had reported it to be (31% vs. Linda C. In this study, unlike the 1993 case report, primidone affected manic symptoms—especially insomnia, anxiety, and racing thoughts—and only on manic symptoms. Schaffer, and J.

It should be noted that a plurality of subjects were also given methylphenobarbital in addition to or instead of primidone. In March 1993, S.G. Hayes of the University of Southern California School of Medicine reported that nine out of twenty-seven people (33%) with either treatment-resistant depression or treatment-resistant bipolar disorder had a permanent positive response to primidone.

The 2002 case focuses on hypocalcemia stemming from such treatment in an adolescent male. The primidone he had been taking suppressed his hypocalcemia-induced QT prolongation. The second case report, published in the December 1986 issue of Zhonghua Xin Xue Guan Bing Za Zhi, describes four cases, men, women, adults and adolescents, who were put on primidone for LQTS.

In addition to all of the above, primidone can cause arthralgia. The risk of fractures is higher for people taking enzyme-inducing anticonvulsants than for people taking non-enzyme-inducing anticonvulsants. Anticonvulsants affect the bones in many ways. Anticonvulsants also contribute to the increased rate of fractures by causing somnolence, ataxia, and tremor which would cause gait disturbance, further increasing the risk of fractures on top of the increase due to seizures and the restrictions on activity placed on epileptic people.Increased fracture rate has also been reported for carbamazepine, valproate and clonazepam. They cause hypophosphatemia, hypocalcemia, low Vitamin D levels, and increased parathyroid hormone.

Her last two episodes were nineteen weeks apart, lasting twenty-five and twenty-seven days, respectively. Five months later, Brown, Stone, and Rathbone published a case report titled, "Primidone and rapid cycling affective disorders" describing a 62-year-old woman who had rapid-cycling bipolar disorder starting in 1978. At the age of fifty-eight, she was started on 125 mg/day of primidone for hand tremor. Lithium treatment was started two years later, but it only eliminated the manic swings, leaving her depressions unaffected. Her depression, which was resistant to all the antidepressants she tried, gradually remitted during primidone therapy; the expected depressive episode lasted three days instead of 13-17. She had been free of depression for two and a half years before the case report was written up. No antidepressant eliminated all her symptoms. Eight weeks later, she had an episode lasting twenty-eight days. Between 1980 and 1989, the patient had six to ten episodes a year, each lasting between eleven and twenty-four days that left her with little energy, made tasks seem more arduous than they actually were, a smaller appetite, a tendency to sleep too much, anxious, and weepy. It was during the final episode, in the middle of 1990, that her dose of primidone was stabilized at 500 mg/day.

In addition to increasing the risk of megaloblastic anemia, primidone, like other older anticonvulsants also increases the risk of neural tube defects, and like other enzyme-inducing anticonvulsants, it increases the likelihood of cardiovascular defects, and cleft lip without cleft palate. Epileptic women are generally advised to take folic acid, but there is conflicting evidence regarding the effectiveness of vitamin supplementation in the prevention of such defects.

Additionally, a coagulation defect resembling Vitamin K deficiency has been observed in newborns of mothers taking primidone. Because of this, primidone is a Category D medication.

Her 16-year-old niece was started on primidone after an unsuccessful trial of phenytoin. The phenobarbital and phenytoin were then combined with atropine and acetyl strophanthidin. The primidone suppressed the fibrillations and lengthened the QT interval for two years and eight months in the patient. The first case report in which the shortening of the QT interval by primidone was documented, published in the July 1980 issue of Annals of Internal Medicine, involved three patients, a 31-year-old woman, her 15-year-old nephew, and his 16-year-old sister. The woman still had ventricular fibrillation, syncope, and seizures even after the removal of her left slate ganglion and a thoracic chain dissection. It was after this that primidone was substituted for phenytoin. Following this, her 15-year-old nephew, the niece's brother, was started because of family history. A month later, she was admitted to the hospital for phenytoin toxicity, where it was found that she had slow spike and abortive wave activity in her left temporal lobe. When this failed, the atropine and acetyl strophanthidin were replaced with lidocaine prior to the surgery. The procainamide was replaced with propanolol, which in turn replaced the propanolol when the latter brought the tachycardia back almost instantaneously upon the first dose. The woman had previously been tried on a combination of phenobarbital and phenytoin when she was thought to have only seizures, followed by phenobarbital combined phenytoin and procainamide. After the surgery, the QT-prolongation returned, so the phenytoin was doubled to 200 mg four times daily.

Lund also noted that it was equally prevalent in individuals with idiopathic and symptomatic epilepsy and that the severity of the epilepsy did not matter. Dupuytren's contracture, a disease of the fasciae in the palm and fingers that permanently bends the fingers (usually the little and ring fingers) toward the palm, was first noted to be highly prevalent in epileptic people in 1941 by a Dr. However, only one quarter of the women were affected vs. Thirty-five years later, Critcheley et al. half of the men. Hart and Hooper speculate that this is also true of gout due to the use of allopurinol This is the only susceptibility factor that is generally agreed upon. They suspected that this was due to phenobarbital therapy, and that the phenobarbital was stimulating peripheral tissue growth factors. People with rheumatoid arthritis are less likely to get this, and Drs. It has also been associated with alcoholism, heavy smoking, diabetes mellitus, physical trauma (either penetrating in nature or due to manual labor), tuberculosis, and HIV. Dupuytren's contracture is almost exclusively found in Caucasians, especially those of Viking descent, and highest rates are reported in Northern Scotland, Norway, Iceland, and Australia. Lund, fourteen years before primidone was on the market. Anticonvulsants do not seem to increase the incidence of Dupuytren's contracture in non-whites. reported a correlation between how long a patient had had epilepsy and his or her chance of getting Dupuytren's contracture.

none among the thirty-seven people taking none) —was similar to that expected in elderly people. The authors speculated that this was due to improvements in diet, sun exposure and exercise in response to earlier findings, and/or that this was because it was sunnier in London than in the Northern European countries which had earlier reported this effect. In any case, the use of more than one anticonvulsant has been associated with an increased prevalence of bone disease in institutionalized epilepsy patients versus institutionalized people who did not have epilepsy. Likewise, postmenopausal women taking anticonvulsants have a greater risk of fracture than their drug-naive counterparts. Primidone, along with phenytoin and phenobarbital, is one of the anticonvulsants most heavily associated with bone diseases such as osteoporosis, osteopenia (which can precede osteoporosis), osteomalacia and fractures. The populations usually said to be most at risk are institutionalized people, postmenopausal women, older men, people taking more than one anticonvulsant, and children, who are also at risk of rickets. However, it has been suggested that bone demineralization is most pronounced in young people (25–44 years of age) and one 1987 study of institutionalized people found that the rate of osteomalacia in the ones taking anticonvulsants—one out of nineteen individuals taking an anticonvulsant (vs.

Primidone also causes exfoliative dermatitis, Stevens–Johnson syndrome, and toxic epidermal necrolysis. Less than 1% of primidone users will experience a rash. The rate is comparable to that of felbamate, vigabatrin, and topiramate. Compared to carbamazepine, lamotrigine, and phenytoin, this is very low.

The massive crystalluria that sometimes occurs sets its symptom profile apart from that of phenobarbital. The symptoms of primidone poisoning have generally been attributed to its biotransformation to phenobarbital; however, primidone has toxic effects independent of its metabolites in humans. The most common symptoms of primidone overdose are coma with loss of deep tendon reflexes and, during the recovery period, if the patient survives, disorientation, dysarthria, nystagmus, and ataxia, lethargy, somnolence, vomiting, nausea, and occasionally, focal neurological deficits which lessen over time. The crystals are white, needle-like, shimmering, hexagonal plates consisting mainly of primidone. Complete recovery comes within five to seven days of ingestion.

Primidone ( INN, BAN, USP ) is an anticonvulsant of the barbiturate class. The active metabolites, phenobarbital, p -hydroxyphenobarbital, and phenylethylmalonamide, are also anticonvulsants. Primidone was once a mainstay anticonvulsant in the treatment of partial and generalized seizures and was the treatment of choice for secondarily generalized seizures originating in the temporal lobes, especially when combined with phenytoin, but by the early 1980s, carbamazepine had surpassed it in popularity due to the latter's lower incidence of sedation. It is a structural analog of phenobarbital and related to barbiturate-derivative anticonvulsants. As time passed and more and more anticonvulsants came on the market, primidone was pushed further and further away from its former place of prominence, and major Western pharmaceutical corporations became less and less interested in manufacturing and selling it. It has largely fallen into disuse in the developed world as more and more anticonvulsants entered the market, and it has been withdrawn from various markets around the world.

Primidone has veterinary uses, including the prevention of aggressive behavior and cannibalism in gilt pigs, and treatment of nervous disorders in dogs and other animals.

Primidone, like phenobarbital and the benzodiazepines, can also cause sedation in the newborn and also withdrawal within the first few days of life; phenobarbital is the most likely out of all of them to do that.

Both drugs are well studied for this condition, unlike other therapies, and are recommended for initial treatment. Primidone is considered to be a first-line therapy for essential tremor along with propranolol. In terms of tremor amplitude reduction, it is just as effective as propranolol, reducing it by 50%. 25 mg/day (low-dose therapy) is just as good as 75 mg/day (high-dose therapy).

Primidone has been compared to carbamazepine, phenytoin, phenobarbital, mephobarbital, ethotoin, metharbital, and mephenytoin. Compared to carbamazepine, primidone has been found to be equally effective, less effective at controlling partial seizures but just as effective at controlling generalized tonic-clonics, less likely to cause side effects but more likely to cause side effects requiring withdrawal of the drug, half as likely to reduce seizures in patients being considered for surgery by at least 80%, more likely to cause depression, significantly more likely cause intolerable side effects, more likely to cause impotence and decreased libido, and cause more adverse effects on motor performance and attention/concentration tests. Open-label case series have suggested that primidone is effective in the treatment of epilepsy. In adult comparison trials, primidone had a higher incidence of intolerable side effects than phenytoin, a higher incidence of decreased libido and impotence, similar control of tonic-clonic seizures, more likely to cause nausea, vomiting, dizziness, and sedation; twice as likely to be effective in controlling seizures in epilepsy surgery candidates, more acute effects such as nausea, vomiting, dizziness, and sedation, and to be just as effective.

The second recurrence, induced by phenobarbital, killed her within five weeks of onset. The second one was a case report of a woman taking primidone and then phenobarbital for trigeminal neuralgia. The first, published in the October 10, 1957 issue of Gazette Médicale de France, has no abstract. She developed toxic epidermal necrolysis, as well as endocarditis and gastrointestinal hemorrhage. Unlike carbamazepine, there are few case reports mentioning the use of primidone in the treatment of trigeminal neuralgia.

Many of these drugs were less effective (according to Table 1), but a few were not. Other pharmacological agents include alprazolam (Xanax), clonazepam (Klonopin), atenolol, sotalol, nadolol, clozapine, nimodipine, and botilinum toxin A. Only propranolol has been compared to primidone in a clinical trial. Primidone is not the only anticonvulsant used for essential tremor; the others include topiramate (Topamax) and gabapentin (Neurontin).

This antagonistic effect is not due to the inhibition of dihydrofolate reductase, the enzyme responsible for the reduction of dihydrofolic acid to tetrahydrofolic acid, but rather to defective folate metabolism.

A randomized controlled trial whose results were published in the July 1985 issue of The New England Journal of Medicine found that primidone was more likely to cause impotence than phenytoin, carbamazepine, or phenobarbital. Like phenytoin, primidone is rarely associated with lymphadenopathy. This is much more common with the valproates than with any of the barbiturates. Primidone can also cause vomiting; this happens in 1.0–0.1% of users. Additionally, her phenobarbital levels were inexplicably elevated post-surgery. Hyperammonemic encephalopathy was reported by Katano Hiroyuki of the Nagoya City Higashi General Hospital in early 2002 in a patient who had been stable on primidone monotherapy for five years before undergoing surgery for astrocytoma, a type of brain tumor.

Transient nausea and vomiting are also common side effects. These side effects are the most common, occurring in more than 1% of users. Primidone can cause drowsiness, listlessness, ataxia, visual disturbances, nystagmus, headache, and dizziness.

In 1965, Monroe and Wise reported using primidone along with a phenothiazine derivative antipsychotic and chlordiazepoxide in treatment-resistant psychosis. What is known is that ten years later, Monroe went on to publish the results of a meta-analysis of two controlled clinical trials on people displaying out-of-character and situationally inappropriate aggression, who had abnormal EEG readings, and who responded poorly to antipsychotics; one of the studies was specifically mentioned as involving psychosis patients. When they were given various anticonvulsants not only did their EEGs improve, but so did the aggression.

The anticonvulsant users who get this also tend to eat monotonous diets devoid of fruits and vegetables. Megaloblastic anemia is actually a group of related disorders with different causes that share morphological characteristics—enlarged red blood cells with abnormally high nuclear-cytoplasmic ratios resulting from delayed maturation of nuclei combined with normal maturation of cytoplasm, into abnormal megakaryocytes and sometimes hypersegmented neutrophils ; regardless of etiology, all of the megaloblastic anemias involve impaired DNA replication. Granulocytopenia, agranulocytosis, and red-cell hypoplasia and aplasia, and megaloblastic anemia are rarely associated with the use of primidone.

Primidone has other cardiovascular effects in beyond shortening the QT interval. Both it and phenobarbital are associated with elevated serum levels (both fasting and six hours after methionine loading) of homocysteine, an amino acid derived from methionine. This is almost certainly related to the low folate levels reported in primidone users. In 1985, both drugs were also reported to increase serum levels of high density lipoprotein (HDL) cholesterol, total cholesterol, and apolipoproteins A and B. Elevated levels of homocysteine have been linked to coronary heart disease.

Nine patients responded only to chlordiazepoxide and four responded to neither drug. The best results were obtained in athetosis and rigidity. Primidone has been used in cerebral palsy. Thorn reported in 1962 that sixteen patients responded favorably to both primidone and chlordiazepoxide and four to only primidone. In 1953, Plum and Sparup found that out of thirty-three patients, twenty had a favorable or moderate response.